Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Financial institution of America World Healthcare Convention 2025 September 23, 2025 6:35 AM EDT
Firm Members
Eric Crombez – Chief Medical Officer & Govt VP
Convention Name Members
Tazeen Ahmad – BofA Securities, Analysis Division
Presentation
Tazeen Ahmad
BofA Securities, Analysis Division
Good morning to everyone listening in. Welcome to the Financial institution of America Healthcare Convention. I’m Tazeen Ahmad, one of many senior SMID biotech analyst. It’s my pleasure to have with me our subsequent presenting firm, Ultragenyx. Presenting for Ultragenyx and sitting with me is Eric Crombez, who’s Chief Medical Officer.
Eric, thanks for making the journey over from the — [indiscernible] not as far.
Query-and-Reply Session
Tazeen Ahmad
BofA Securities, Analysis Division
There’s lots occurring at Ultragenyx. There’s been loads of questions being as I suppose, two of your packages, OI and Angelman. And so not a shock, we’ll spend many of the subsequent 40 minutes or so speaking about that.
Earlier than I try this although, perhaps since you have had so many conversations with of us at this level, are you able to simply give us an outline of each the OI and AS packages, the place you stand with these, after which we’ll go into specifics on every, if that is okay.
Eric Crombez
Chief Medical Officer & Govt VP
Sure. I suppose beginning somewhat bit so as. So osteogenesis imperfecta for the OI, Angelman packages being our large worth drivers after which additionally together with the gene remedy packages.
However specializing in osteogenesis imperfecta, we clearly didn’t clear our second interim evaluation, and we introduced that earlier within the yr that leads us to full research readout. We’re saying we are going to speak about that externally across the finish of the yr, and we outline round finish of the yr at December or January. Actually, we share
